Pernix Therapeutics (NASDAQ:PTX) will be issuing its Q3 quarterly earnings data after the market closes on Thursday, November 8th.
Pernix Therapeutics (NASDAQ:PTX) last released its earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($1.13) earnings per share for the quarter. The firm had revenue of $21.09 million during the quarter.
Pernix Therapeutics stock opened at $0.79 on Wednesday. Pernix Therapeutics has a 52 week low of $0.59 and a 52 week high of $3.30.
Separately, ValuEngine raised Pernix Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 20th.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/pernix-therapeutics-ptx-to-release-quarterly-earnings-on-thursday.html.
About Pernix Therapeutics
Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry.
Featured Article: Discount Rate
Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.